MEC Practice Academy 11.19
|Articles|March 5, 2010

FDA clears first point-of-care allergy test device

The Food and Drug Administration granted clearance to market the first point-of-care device to diagnose allergies in the offices with a moderate complexity lab.

The Food and Drug Administration (FDA) granted clearance to market the first point-of-care device to diagnose allergies in the offices with a moderate-complexity lab.

Uppsala, Sweden-based Phadia earned the clearance to sell its ImmunoCAP Rapid System. With the system, physicians who treat patients who have asthma and rhinitis will have semi-quantitative measurements of IgE levels for 10 common inhalant allergens in the United States in about 20 minutes, according to the company.

Retail prices for the ImmunoCAP Rapid System, which has been used in Europe for three years, were not available.


Related to this article

Tennessee practice to pay $2.8M over nonphysician billing; flu season gets a head start; cannabis tied to higher stroke odds — Morning Medical Update © everythingpossible - stock.adobe.com
The top news stories in medicine today: A Tennessee multi-physician practice agrees to pay $2.8 million to resolve allegations it billed nonphysician practitioners' services under physicians' provider numbers; CDC data show an early start to flu season; cannabis use is tied to higher stroke odds in an American Heart Association abstract.